Hyzetimibe - Zhejiang Hisun Pharmaceutical

Drug Profile

Hyzetimibe - Zhejiang Hisun Pharmaceutical

Alternative Names: HS-25

Latest Information Update: 27 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Zhejiang Hisun Pharmaceutical
  • Class Antihyperlipidaemics
  • Mechanism of Action Cholesterol absorption inhibitors; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Hypercholesterolaemia

Highest Development Phases

  • Phase III Hypercholesterolaemia
  • No development reported Hyperlipidaemia

Most Recent Events

  • 14 Mar 2018 Zhejiang Hisun Pharmaceutical completes enrolment in a phase III trial for Hypercholesterolemia (NCT03464682)
  • 27 Feb 2018 Hyzetimibe is available for licensing in World as of 27 Feb 2018. http://hisunusa.com/products-services/specialty-products/coronary-heart-disease-chd-overview/
  • 14 Feb 2018 Zhejiang Hisun Pharmaceutical completes enrolment in a phase III trial for Hypercholesterolemia (NCT03433196)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top